Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. Our clinical-stage product candidates include: Phase 3 HEPLISAV-B ™ Adult Hepatitis B Vaccine Phase 1/2 Cancer Immunotherapy Phase 2 Asthma Therapy - Partnered with AstraZeneca In Europe, Dynavax manufactures Hepatitis B surface antigen for HEPLISAV-B.

Type
Public
HQ
Berkeley, US
Size (employees)
234 (est)
Dynavax Technologies is headquartered in Berkeley, US

Dynavax Technologies Office Locations

Dynavax Technologies has office in Berkeley
Berkeley, US

Dynavax Technologies Metrics

Dynavax Technologies Summary

Market capitalization

$156 M

Closing share price

$3.95
Dynavax Technologies's current market capitalization is $156 M.

Dynavax Technologies Market Value History

Dynavax Technologies Company Life

You may also be interested in